Around 300 drugs exempt from regular price cut under new Japanese provisions
This article was originally published in Scrip
Around 300 products will escape a reduction in the next regular revision of reimbursement prices for prescription drugs in Japan on April 1st because they meet certain criteria under complex new rules being adopted on a trial basis this year.
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.